What are important considerations in the preoperative period for liver disease?

What are important considerations in the preoperative period for liver disease?

• A. Assess hepatic function
• B. Coagulopathy risk
• C. Drug metabolism
• D. All of the above

Answer: (D)

In the preoperative period for liver disease, the patient’s hepatic reserve, bleeding risk, and drug handling drive planning. First, assess hepatic function to estimate how well the liver can cope with surgery and anesthesia. Key lab tests (bilirubin, albumin, INR, ALT/AST) and scoring systems (such as Child-Pugh or MELD) help gauge the extent of liver impairment, predict postoperative liver failure risk, and guide decisions about susceptibility to infections, wound healing, and fluid management. Also evaluate for portal hypertension and ascites, which influence intraoperative strategies and hemodynamic management. Second, coagulopathy risk must be considered because the liver makes most clotting factors. Liver disease can create a bleeding tendency even when platelet counts seem adequate, so preoperative assessment of coagulation status is essential and planning should include correcting deficiencies (e.g., vitamin K, plasma, platelets if indicated) and choosing techniques that minimize bleeding. This also affects decisions about regional anesthesia versus general anesthesia and the need for ready access to blood products. Third, drug metabolism is significantly altered since the liver is a primary site for processing many anesthetics, analgesics, and perioperative medications. Reduced hepatic blood flow and impaired enzyme activity prolong drug effects and increase toxicity risk. Therefore, adjust dosing, favor drugs with safer hepatic profiles, monitor closely for sedation and hemodynamic effects, and review all medications for potential hepatotoxic interactions. All of these aspects together guide safe perioperative management in liver disease.

In the preoperative period for liver disease, the patient’s hepatic reserve, bleeding risk, and drug handling drive planning. First, assess hepatic function to estimate how well the liver can cope with surgery and anesthesia. Key lab tests (bilirubin, albumin, INR, ALT/AST) and scoring systems (such as Child-Pugh or MELD) help gauge the extent of liver impairment, predict postoperative liver failure risk, and guide decisions about susceptibility to infections, wound healing, and fluid management. Also evaluate for portal hypertension and ascites, which influence intraoperative strategies and hemodynamic management.

Second, coagulopathy risk must be considered because the liver makes most clotting factors. Liver disease can create a bleeding tendency even when platelet counts seem adequate, so preoperative assessment of coagulation status is essential and planning should include correcting deficiencies (e.g., vitamin K, plasma, platelets if indicated) and choosing techniques that minimize bleeding. This also affects decisions about regional anesthesia versus general anesthesia and the need for ready access to blood products.

Third, drug metabolism is significantly altered since the liver is a primary site for processing many anesthetics, analgesics, and perioperative medications. Reduced hepatic blood flow and impaired enzyme activity prolong drug effects and increase toxicity risk. Therefore, adjust dosing, favor drugs with safer hepatic profiles, monitor closely for sedation and hemodynamic effects, and review all medications for potential hepatotoxic interactions.

All of these aspects together guide safe perioperative management in liver disease.